#LCSM Transcript
Healthcare social media transcript of the #LCSM hashtag.
– ().
See #LCSM Influencers/Analytics.
| Profile | Tweet |
|---|---|
 | NCI Cancer Stats @NCICancerStats Only 16% of #LungCancer cases are diagnosed at the localized stage, when 5-year relative survival is highest. Learn more about this disease here: https://t.co/BVqvN4e1pm #LCSM https://t.co/JhthhKFcnK |
 | OFroh @_OFroh_ RT @NCICancerStats: Only 16% of #LungCancer cases are diagnosed at the localized stage, when 5-year relative survival is highest. Learn more about this disease here: https://t.co/BVqvN4e1pm #LCSM https://t.co/JhthhKFcnK |
 | Candace Skrapek @cskraps RT @tmprowell: Patient advocate extraordinaire (& friend) @ivybelkins on how her dx of mets #lungcancer & #advocacy taught her kids tolerance of uncertainty & how to live meaningfully in the face of adversity. If you are a dr & not following advocates, you are missing out. #lcsm @EGFRResisters |
 | Aki Alzubaidi @aki_alzubaidi RT @eonhealth: Our #ATS2019 Webinar with @mcuban has been moved to Monday 5/20 @ 9 AM. As a family company, we don't want you to work on a Sunday. We hope that more of you can now join us! Let's talk #healthtech issues & innovative solutions. Together we can #DefyDisease #LCSM #HCSM #HCIT https://t.co/a61esjODlS |
 | Dr. Karen Kane McDonnell @KarenKane6 Thanks for posting, Ivy. |
 | OncLive SOSS @OncLiveSOSS Consolidative treatment for oligometastatic NSCLC is currently supported by retrospective, single-arm prospective, and small number of phase II randomized data -Dr. Daniel Gomez, of @sloan_kettering #lcsm #lcnsc https://t.co/eUfFZ5Rgep |
 | Biniam Kidane @biniamkidaneMD RT @VGupta_MD: Our review of patient-reported outcomes in #lungcancer and #esophagealcancer in this issue too👇🏽 @dhirparaMD @LisaBrownMD @biniamkidaneMD #lcsm #tssmn |
| OncLive SOSS @OncLiveSOSS We also spoke with Dr. Daniel Gomez, of @sloan_kettering, who shared important updates in the management of oligometastatic disease. Interview to come! Stay tuned. #stateofscience #lcsm #lcnsc https://t.co/Rta6iYUEq8 |
 | Oncopedia @onco_pedia RT @RielyMD: #ASCO19 data on newer MET inhibitors for MET Exon 14 altered lung cancer Numbers too small to say if better/worse than crizotinib #lcsm tepotinib 1st line RR 67%, overall RR 51% https://t.co/bxQewAK2oR capmatinib 1st line RR 71%, 2nd/3rd line RR 39% https://t.co/NpCdK0sJrw |
 | Paula A @paulalv RT @ros1cancer: "The ROS1ders Interview Dr. Ross Camidge" via Zoom Webinar on the burning questions of experienced #ROS1 #cancer patients. Thanks to @TheALCF for their technical assistance! #LCSM #beatlungcancer https://t.co/zHDpcpOZyk |
| Paula A @paulalv RT @LungProject: Thanks for participating – the answer is A! Among never-smokers, women get #lungcancer more frequently than men. Learn more about how this disease affects women and talk to your doctor if you think you or a loved one are at-risk. @LCAorg #NWHW #lcsm https://t.co/o86PPxsrwU https://t.co/K4EUlkYsR9 |
| OncLive SOSS @OncLiveSOSS We also spoke with Dr. Daniel Gomez, of @sloan_kettering, who shared important updates in the management of oligometastatic disease. Interview to come! Stay tuned. #stateofscience #lcsm #lcnsc https://t.co/tFcO2Frng2 |
 | Patty Watkins @Pattybeatslungc RT @ros1cancer: "The ROS1ders Interview Dr. Ross Camidge" via Zoom Webinar on the burning questions of experienced #ROS1 #cancer patients. Thanks to @TheALCF for their technical assistance! #LCSM #beatlungcancer https://t.co/zHDpcpOZyk |
#LCSM content from Twitter.